Phathom Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Strategic Pivot to Access and Financial Sustainability

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

• Achieved a second consecutive quarter of positive cash flow and positive operating profit, excluding stock-based compensation., signaling a successful transition toward a self-sustaining financial model.

• Revenue for Q3 grew 71% year-over-year to $84.7 million, while covered prescription volume grew 19% sequentially compared to Q2 2026.

• Launched the 'Access First' initiative to address the primary adoption hurdle: physician and patient perceptions regarding prescription effort and affordability.

• Shifted the sales force focus toward educating healthcare providers on prior authorization logistics and the benefits of the BlinkRx pharmacy partnership.

• Introduced a $0 copay offering for commercially insured patients through BlinkRx to remove cost-based decision barriers compared to generic PPIs.

• Reached the milestone of two million total prescriptions filled, with the second million achieved in less than half the time of the first million.

• Maintained a disciplined expense profile while investing in targeted commercial initiatives and late-stage clinical trials for market expansion.

Growth Outlook and Pipeline Milestones

• Reiterated full-year 2026 revenue guidance of $310 million to $325 million, with gross-to-net discounts expected at the lower end of the 55% to 59% range.

• Anticipates reaching durable positive cash flow in 2027, supported by top-line growth outpacing moderate increases in operating expenses.

• Expects Phase II top-line data for Eosinophilic Esophagitis (EoE) in Q4 2026, which could support a pediatric exclusivity extension and market expansion.

• Maintains a long-term strategic focus on building a comprehensive GI portfolio through potential M&A or licensing of Phase II/III assets before 2033.

• Assumes the entry of a second PCAB competitor in 2027 will serve as a market tailwind by increasing overall category awareness and physician adoption.

Legal and Operational Context

• Intervened in litigation filed by BDR Pharmaceuticals challenging the FDA's grant of 10-year NCE exclusivity for VOQUEZNA under the GAIN Act.

• Reported a gross margin of 78%, slightly below the 80% target due to one-time manufacturing charges included in the cost of revenues.

• Noted an IQVIA methodology adjustment for prescription data reporting, a standard update as brands mature that took effect in October.

• Shifted to a new cash holding covenant of approximately $119 million as of October 1, 2026, following the terms of the Revenue Interest Financing Agreement.